Malaysian Ministry of Health Awards Biocon Biologics Insugen® Human Insulin Three-Year Contract

Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd., announced on Tuesday that its subsidiary Biocon Sdn. Bhd in Malaysia has been awarded a three-year contract, worth 90 million USD (375 million MYR), for its recombinant human insulin brand Insugen®, by the Malaysian Ministry of Health (MoH).

According to the company’s press release, Biocon Sdn. Bhd will supply its insulins to its partner Duopharma Marketing Sdn. Bhd. (DMktg). It is a subsidiary of Duopharma Biotech which is a pharmaceutical and biotechnology company in Malaysia.

Additionally, Biocon Biologics’ Insugen formulations will be available to patients at all government hospitals, district health offices and health clinics.

“We are delighted to renew our commitment to provide affordable access to our recombinant human insulin to people with diabetes in Malaysia through this new government contract. This will allow us to serve over 400,000 people with diabetes using recombinant human insulin, helping the government on its journey towards equitable access to diabetes care,” said Susheel Umesh, Commercial Director, Emerging Markets, Biocon Biologics, in a statement.

Meanwhile, rh insulin formulations, Insugen®-R, Insugen®-N and Insugen®-30/70, are manufactured at Biocon Sdn. Johor facility of Bhd. Moreover, they have been approved by the National Medicines Regulatory Authority (NPRA) in Malaysia.

Biocon Biologics also informed that it provides affordable access to these lifesaving therapies to patients in many developed markets like the US, EU, Australia, as well as many emerging countries in the Middle East and India. Latin America through its quality human insulin and other products made in Malaysia.